A randomized controlled trial of recombinant interferon-beta 1a in Guillain-Barré syndrome

Neurology. 2003 Nov 11;61(9):1282-4. doi: 10.1212/01.wnl.0000092019.53628.88.

Abstract

The authors recruited 19 nonambulant patients with Guillain-Barré syndrome into a pilot, double-blind, randomized, placebo-controlled safety trial of interferon beta 1a (IFN[beta]-1a) (Rebif). Participants received IFN[beta]-1a or placebo subcutaneously three times weekly, 22 microg for the first week and then 44 microg for up to 24 weeks, in addition to IV immunoglobulin (IVIg). IFN[beta] did not have any unexpected interaction with IVIg and there was no significant difference in rate of improvement.

Publication types

  • Clinical Trial
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cytokines / blood
  • Disability Evaluation
  • Dose-Response Relationship, Drug
  • Fatigue / chemically induced
  • Female
  • Guillain-Barre Syndrome / drug therapy*
  • Guillain-Barre Syndrome / immunology
  • Humans
  • Immunoglobulins, Intravenous / therapeutic use
  • Interferon beta-1a
  • Interferon-beta / adverse effects
  • Interferon-beta / therapeutic use*
  • Lymphopenia / chemically induced
  • Male
  • Middle Aged
  • Pilot Projects
  • Recombinant Proteins / adverse effects
  • Recombinant Proteins / therapeutic use*
  • Treatment Outcome

Substances

  • Cytokines
  • Immunoglobulins, Intravenous
  • Recombinant Proteins
  • Interferon-beta
  • Interferon beta-1a